Literature DB >> 16331666

A scoring system based on the expression of six surface molecules allows the identification of three prognostic risk groups in B-cell chronic lymphocytic leukemia.

Antonella Zucchetto1, Riccardo Bomben, Michele Dal Bo, Paolo Sonego, Paola Nanni, Maurizio Rupolo, Pietro Bulian, Luigino Dal Maso, Giovanni Del Poeta, Maria Ilaria Del Principe, Massimo Degan, Valter Gattei.   

Abstract

We have previously identified 12 surface antigens whose differential expression represented the signature of B-cell chronic lymphocytic leukemia (B-CLL) subsets with different prognosis. In the present study, expression data for these antigens, as determined in 137 B-CLL cases, all with survivals, were utilized to devise a comprehensive immunophenotypic scoring system of prognostic relevance for B-CLL patients. In particular, univariate z score was employed to identify the markers with greater prognostic impact, while maximally selected log-rank statistics were chosen to define the optimal cut-off points capable to split patients into two groups with different survivals. A weighted immunophenotypic scoring system was developed by integrating results from these analyses. Six antigens were selected: three positive prognosticators (CD62L, CD54, CD49c) and three negative prognosticators (CD49d, CD38, CD79b), with cut-off values ranging from 30% to 50% of positive cells. By weighing the expression of each marker according to its statistical power, a complete scoring system, with point values comprised between 0 (complete absence of phenotypic conditions associated with good prognosis) and 9 (all the phenotypic conditions associated with good prognosis fulfilled), allowed to split the whole set of B-CLL patients, into three distinctive prognostic groups (P = 4.78 x 10(-11)) with high- (score 0-3), intermediate- (score 4-6), and low- (score 7-9) risk of death. The three risk groups showed different distribution of cases as for Rai's stages, IgVH mutations, and ZAP-70 expression. The proposed immunophenotypic scoring system may be an additional useful tool in routine diagnostic/prognostic procedures for B-CLL.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16331666     DOI: 10.1002/jcp.20570

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  14 in total

1.  CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells.

Authors:  Rajendra N Damle; Sonal Temburni; Carlo Calissano; Sophia Yancopoulos; Taraneh Banapour; Cristina Sison; Steven L Allen; Kanti R Rai; Nicholas Chiorazzi
Journal:  Blood       Date:  2007-08-07       Impact factor: 22.113

2.  Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting.

Authors:  Antonina V Kurtova; Archito T Tamayo; Richard J Ford; Jan A Burger
Journal:  Blood       Date:  2009-02-19       Impact factor: 22.113

3.  CD49d associates with nodal presentation and subsequent development of lymphadenopathy in patients with chronic lymphocytic leukaemia.

Authors:  Paolo Strati; Sameer A Parikh; Kari G Chaffee; Sara J Achenbach; Susan L Slager; Timothy G Call; Wei Ding; Diane F Jelinek; Curtis A Hanson; Neil E Kay; Tait D Shanafelt
Journal:  Br J Haematol       Date:  2017-04-07       Impact factor: 6.998

4.  CD69 is independently prognostic in chronic lymphocytic leukemia: a comprehensive clinical and biological profiling study.

Authors:  Giovanni Del Poeta; Maria Ilaria Del Principe; Antonella Zucchetto; Fabrizio Luciano; Francesco Buccisano; Francesca Maria Rossi; Antonio Bruno; Annalisa Biagi; Pietro Bulian; Luca Maurillo; Benedetta Neri; Riccardo Bomben; Cristina Simotti; Angela Maria Coletta; Michele Dal Bo; Paolo de Fabritiis; Adriano Venditti; Valter Gattei; Sergio Amadori
Journal:  Haematologica       Date:  2011-10-11       Impact factor: 9.941

5.  SLAMF1 regulation of chemotaxis and autophagy determines CLL patient response.

Authors:  Cinzia Bologna; Roberta Buonincontri; Sara Serra; Tiziana Vaisitti; Valentina Audrito; Davide Brusa; Andrea Pagnani; Marta Coscia; Giovanni D'Arena; Elisabetta Mereu; Roberto Piva; Richard R Furman; Davide Rossi; Gianluca Gaidano; Cox Terhorst; Silvia Deaglio
Journal:  J Clin Invest       Date:  2015-11-30       Impact factor: 14.808

6.  A molecular score by quantitative PCR as a new prognostic tool at diagnosis for chronic lymphocytic leukemia patients.

Authors:  Basile Stamatopoulos; Nathalie Meuleman; Cécile De Bruyn; Karlien Pieters; Géraldine Anthoine; Philippe Mineur; Dominique Bron; Laurence Lagneaux
Journal:  PLoS One       Date:  2010-09-16       Impact factor: 3.240

7.  CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential.

Authors:  Tait D Shanafelt; Susan M Geyer; Nancy D Bone; Renee C Tschumper; Tom E Witzig; Greg S Nowakowski; Clive S Zent; Tim G Call; Betsy Laplant; Gordon W Dewald; Diane F Jelinek; Neil E Kay
Journal:  Br J Haematol       Date:  2008-03       Impact factor: 6.998

8.  Surface-antigen expression profiling of B cell chronic lymphocytic leukemia: from the signature of specific disease subsets to the identification of markers with prognostic relevance.

Authors:  Antonella Zucchetto; Paolo Sonego; Massimo Degan; Riccardo Bomben; Michele Dal Bo; Pietro Bulian; Dania Benedetti; Maurizio Rupolo; Giovanni Del Poeta; Renato Campanini; Valter Gattei
Journal:  J Transl Med       Date:  2006-03-01       Impact factor: 5.531

9.  Prognostic models for newly-diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta-analysis.

Authors:  Nina Kreuzberger; Johanna Aag Damen; Marialena Trivella; Lise J Estcourt; Angela Aldin; Lisa Umlauff; Maria Dla Vazquez-Montes; Robert Wolff; Karel Gm Moons; Ina Monsef; Farid Foroutan; Karl-Anton Kreuzer; Nicole Skoetz
Journal:  Cochrane Database Syst Rev       Date:  2020-07-31

10.  Identification of a 20-gene expression-based risk score as a predictor of clinical outcome in chronic lymphocytic leukemia patients.

Authors:  Elias Bou Samra; Bernard Klein; Thérèse Commes; Jérôme Moreaux
Journal:  Biomed Res Int       Date:  2014-05-05       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.